SULLA
LOE ApproachingNDAORALTABLET
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULLA is an oral tablet small molecule approved by Bayer in 1966 with an unknown mechanism of action and indication profile. The drug's precise therapeutic target and clinical use are not specified in available data. It represents a legacy product from the mid-20th century pharmaceutical era.
LOE Approaching
With LOE approaching and 30% competitive pressure, the brand team is likely in defense/optimization mode with limited growth investment and smaller commercial headcount compared to growth-stage products.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SULLA currently has zero linked job openings, reflecting its mature, declining lifecycle stage. Career opportunities on this product are limited and focused on defensive commercial management rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on SULLA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.